Keep Risk of Heart Problems With Cholinesterase Inhibitors in Perspective

October 2022

A new Health Canada warning will spur questions about the risk of heart problems with donepezil, galantamine, or rivastigmine.

About 3 million Rxs for these cholinesterase inhibitors are dispensed in Canada each year...usually for Alzheimer’s or Parkinson’s dementia.

Labelling for these meds already warns about slow heart rate. Now there’ll be warnings about QT prolongation and torsades...which can lead to serious irregular heart rhythms or even sudden death.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Influenza Know What’s Changed With Flu Immunizations for 2022-2023
COVID-19 Help Patients Get Up to Date With Moderna’s Bivalent COVID-19 Booster
Allergic Reactions Dig Deeper When a Patient Reports a Sulfa Allergy
Storage & Disposal Work as a Team to “Maintain the Cold Chain”
Adverse Events Keep Risk of Heart Problems With Cholinesterase Inhibitors in Perspective
Lupus Be Familiar With Saphnelo for Lupus
Gastroenterology Know Which Meds Treat…or Worsen…Gastroparesis
NSAIDs Consider Kidney Risks for Patients on NSAIDs
Hypotension Minimize Mishaps With Meds for Orthostatic Hypotension

Keep Risk of Heart Problems With Cholinesterase Inhibitors in Perspective

Practical advice for a better career, with unlimited access to CE

Table of Contents